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 Chapter 22 
 Intestinal Crypt Organoids as Experimental 
Models 
 Sabina  Lukovac and  Guus  Roeselers 
 Abstract  When it comes to studying the effect of food bioactives on gut health, one 
of the essential steps that needs to be assessed is characterizing specifi c effects of 
the bioactives on the physical barrier of the lumen, the gastrointestinal tissue. In 
addition to studying the effects on transport function (e.g. by using Ussing cham-
bers or cell culture systems), it is of great interest to evaluate the effects on mor-
phology, cell biology, gene expression, and relevant functions of different cell types 
that are resident in the gastrointestinal (GI) tract. An ideal near- physiological model 
should contain a mixture of different GI epithelial cells (e.g. Paneth cells, goblet 
cells, absorptive and hormone secretive epithelial cells), which can be cultured 
indefi nitely. Recently, the culture and applications of long-term primary multi-cel-
lular cluster structures gastrointestinal organoids (or enteroids) have been demon-
strated, and within the last 5 years the number of researchers that commonly use this 
tissue culture model has increased rapidly. This multi-cellular system may be a 
promising addition for existing ex vivo and alternative for animal models for testing 
effects of food bioactives on the intestinal tissue, and could provide a model for pre-
screening of compounds prior to moving to the large scale testing systems. Moreover, 
intestinal organoids can be cultured from different species (e.g. human, pig and 
mouse). In this chapter we will focus on organoids cultured from mouse and pig 
crypt cells. We will give a short overview on how to isolate, culture, incubate, and 
apply them in different research fi elds. 
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22.1  Gastrointestinal Organoids 
 Several attempts have been made to isolate the proliferative regions of the intestinal 
epithelium from different species (e.g. mouse, porcine, human) (Pageot et al.  2000 ; 
Agopian et al.  2009 ). Proliferative regions of the intestinal epithelium consist of the 
transit amplifying cells, which are undifferentiated progenitor cells that can differ-
entiate into all different epithelial cells of the intestinal epithelium. Initially cultured 
intestinal tissue contained crypt and villus domains, resembling the intestinal epi-
thelial architecture present in vivo. However, these cultured intestinal tissue pieces 
from the intestinal epithelial could be maintained in culture for up to several days at 
maximum, and thus were not self-renewing . 
 The need for a self-sustaining, long-term GI model remained. The big break-
through came when Dr. Hans Clevers and colleagues, for the fi rst time, identifi ed the 
intestinal stem cells by thorough lineage tracing experiments (Barker et al.  2007 ). 
These experiments were performed over a period of 60 days in mice, and confi rmed 
the presence of Lgr5 (marker for adult stem cells)-positive stem cells in small intes-
tinal and colonic crypts. These stem cells are able to differentiate in to all intestinal 
epithelial cells (enterocytes, Paneth cells, Goblet cells, enteroendocrine cells, but 
also stem and progenitor cells), as shown in vivo and in culture where these Lgr5-
positive cells formed so-called ‘mini-guts’ or ‘organoids’ (Sato et al.  2009 ) (Fig.  22.1 ). 
 Fig. 22.1  Schematic image of an intestinal organoid. All epithelial cell types normally present 
in vivo are also present in the cultured intestinal organoids, as indicated by different colored cells. 
Figure adapted from Roeselers et al. ( 2013 ) 
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Secretion of mucins into the luminal space and lysozyme production by Panneth 
cells illustrate the functionality of this epithelium (McCracken et al.  2011 ). 
 The discovery of these stem cells opened a new world of the possibilities for GI 
culture methods, by manipulation of these cells. The great potential of these now 
self-sustaining ‘mini-guts’ in the fi eld of transplantation and regenerative medicine 
was immediately evident, and soon engraftment of intestinal organoids in mice was 
successfully performed (Yui et al.  2012 ; Shaker and Rubin  2012 ). So far, the human 
organoid transplantation has not been performed in humans yet, although human 
intestinal organoids can be cultured and maintained in culture for some time now 
(Sato et al.  2011a ). 
 Recently human organoids cultured from induced pluripotent stem cells (iPSCs) 
have been transplanted into mice (in vivo), where intestinal adaptive capacity as well 
as epithelial function (peptide uptake and permeability) have been demonstrated in 
the transplants (Watson et al.  2014 ). In addition, Clevers and colleagues (University 
Medical Center Utrecht, the Netherlands), proposed treatment for children suffering 
from a rare gastrointestinal disease (microvillus inclusion disease) by transplantation 
of stem-cell derived organoids (Wiegerinck et al.  2014 ), but the outcomes of these 
studies have not been published yet. Intestinal organoids have been applied to study 
cystic fi brosis by using primary organoids from cystic fi brosis patients. This model 
facilitates diagnosis, functional studies, drug development and personalized medicine 
approaches in cystic fi brosis (Dekkers et al.  2012 ). 
 Recently, we have demonstrated that intestinal organoids provide a powerful 
model for host–microbiome interaction studies (Lukovac et al.  2014 ). In this study 
we observed that specifi c gut bacteria and their metabolites differentially modulate 
epithelial transcription in mouse organoids (Lukovac et al.  2014 ). 
22.2  General Protocol 
 Isolation of mouse intestinal crypts and organoid culture, adapted from (Sato and 
Clevers  2013 ) is schematically represented in Fig.  22.2 . A detailed protocol of the 
culture protocol is described below. 
22.2.1  Small Intestinal Crypt Isolation 
 Thaw aliquots of Matrigel™ Basement Membrane Matrix (BD Biosciences) on ice 
before isolation and pre-incubate a 24-well plate in a CO 2 -incubator (5 % CO 2 , 
37 °C). Matrigel™ is a solubilized gelatinous protein mixture and is derived from 
the Engelbreth–Holm–Swarm (EHS) mouse sarcoma cells. The extract resembles 
the complex extracellular environment found in many tissues and is commonly used 
as a substrate for culturing cells. At room temperature, Matrigel™ polymerizes into 
a three dimensional structure that is useful for both cell culture and studying cellular 
processes in three dimensions, including cell migration. 
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 Isolate a piece of mouse small intestine (at least 5 cm) and open longitudinally. 
Wash the intestine with ice cold PBS until most of the luminal contents are cleared 
and scrape off the villi using a coverslip. After another washing with ice-cold PBS, 
cut the intestine into 2–4 mm pieces with scissors and transfer them to a 50-mL 
tube. Add 30 mL ice-cold PBS and wash the fragments by gently pipetting the 
fragments up and down with a 10 mL pipette and discard supernatant after settling 
down. Repeat this step 5–10 times until the supernatant is almost clear. Next, add 
30 mL of ice-cold crypt isolation buffer (5 mM EDTA in PBS; one can also use 
higher EDTA concentration, up to 10 mM if yields are low) and gently rock the tube 
at 4 °C for 30 min. Keep pipetting up and down the tissue in solution every 10 min 
in order to release as much epithelium as possible. After settling down the frag-
ments, the supernatant can be removed and 20 mL of ice-cold PBS can be added to 
wash the fragments using a pipet. Repeat this procedure when the fragments are 
settled down, in order to release most of the crypts, that will also settle down after 
some time. Villous fractions present in the supernatant are discarded and crypts 
fractions are passed through a 70-mm cell strainer and collected into 50 mL tube(s), 
after adding 5 % FBS to a crypt solution. Spin down the crypt fractions at 300× g 
5 min and resuspend the pellets in 10 mL of ice-cold basal culture medium (advanced 
Dulbecco’s modifi ed Eagle medium/F12 supplemented with penicillin/streptomycin, 
10 mmol/L HEPES, Glutamax, 1 × N2, 1 × B27, and 1 mmol/L  N -acetylcysteine). 
The suspension is transferred to a 15 mL Falcon tube and centrifuged at 150–200× g 
for 2 min, to remove single cells (mostly lymphocytes), which end up in the supernatant. 
 Fig. 22.2  Schematic summary of intestinal epithelial crypt isolation and subsequent organoid 
cultures 
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This washing step should be repeated 2–3 times until most single cells are cleared. 
After the washing steps, the number of crypts can be calculated (take 10 μL of the 
crypts suspension and count numbers of crypts using a heamocytometer by inverted 
microscopy; the total number of crypts = the number of crypts counted × 1,000). 
It should be noted that at this point it is diffi cult to distinguish true crypts from other 
epithelial debris, hence the count is only a rough estimate. 
22.2.2  Small Intestinal Organoid Culture 
 Centrifuge small intestinal crypts, and remove supernatant as much as possible to 
avoid dilution of Matrigel™ in the next step. Keep the tube at 4 °C and resuspend 
the crypts pellet in Matrigel™ (200–500 crypts/50 μL matrigel). Pipet 50 μL of the 
crypt-Matrigel™ suspension into the pre-warmed 24-well plate. The suspension 
should be applied on the center of the well so a hemispherical droplet can be formed. 
Transfer the plate back into the CO 2 incubator (5 % CO 2 , 37 °C) as soon as possible 
after the seeding. Allow the Matrigel™ to solidify for 5–10 min and add 500 μL 
complete organoid culture medium per well. For preparation of the organoid culture 
medium (e.g. amount of growth factors) check Table  22.1 . Place the 24-wells plate 
in a CO 2 -incubator and refresh the culture medium every 4–6 days.
22.2.3  Small Intestinal Organoid Passage 
 Crypt organoids can be passaged 7–14 days after seeding. Place the plate with 
organoids on ice to allow the matrigel to dissolve. Remove the culture medium and 
gently break up the Matrigel™ by pipetting with a 100–1,000 μL-pipette. Resuspend 
the organoids in 1–2 mL basal culture medium and transfer them to a 15 mL-tube. 
Gently disrupt the organoids using a fi re-polished Pasteur pipette to remove released 
dead cells and single cells. Pellet everything by centrifuging at 300× g for 5 min, and 
wash the organoids afterwards with 10 mL basal culture medium. Pellet again at the 
same speed and add the correct amount of Matrigel™, namely 50 μL per well that 
you would like to plate. Count the “crypts/immature organoids” as described before 
(by hemocytometer) and pipet the Matrigel™  suspension with crypts (50 μL per 
well) into a new 24 culture plate and place the plate back in CO 2 incubator (5 % 
CO 2 , 37 °C) to culture the organoids. 
22.3  Monitoring Viability 
 Organoid culture and development across time after isolation, and post-passage can 
be verifi ed using microscopy. Mainly, the dead cells of the organoid tissue will be 
visible in the central part of the organoid, corresponding to the intestinal lumen 
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in vivo (these aggregates of dead cells can be visualized by microscopy as shown in 
Fig.  22.3 at day 5–7). Figure  22.3 shows a very simplifi ed summary of a mouse 
intestinal crypt development into a mature organoid structure. Additional conforma-
tion of the viability of the organoids can be performed upon by the use of the LDH 
toxicity assay or the immunofl uorescent staining procedures for viability markers 
(e.g. apoptotic caspase 3 staining), but the organoids have to be sampled destruc-
tively in order to perform this assay, thus this step can be only applied at the fi nal 
stages of specifi c experiments. It should be noted that once growth, normal cell 
proliferation and differentiation stops, and organoids start to die, that this will 
immediately become visible, thus it is essential to monitor the organoid growth and 
proliferation on a daily basis. 
 Culture and maintenance of intestinal organoids, relies on the presence and activity 
of mature (intestinal) stem cells. Even though intestinal organoids can be isolated 
 Table 22.1  Concentrations of growth factors and other compounds added to the basal culture 
medium used for mouse and pig organoid culture 
 Reagent (supplier)  Mouse a  Pig 
 Advanced DMEM/F12 (ADF) (Invitrogen, Cat 
#11320-082) 
 1×  1× 
 HEPES buffer (Sigma-Aldrich, Cat #83264-100ML-F)  10 mM  10 mM 
 GlutaMax (Invitrogen, Cat #35050-061)  2 mM  2 mM 
 Penicillin/Streptomycin (Invitrogen, Cat #15070-063)  0.5 U/mL 
(100×) 
 0.5 U/mL (100×) 
 N2 Supplement (Invitrogen, Cat #17502-048)  1× (stock: 100×)  1× (stock: 100×) 
 B-27 Supplement Minus Vitamin A (Invitrogen, Cat 
#12587-010) 
 1× (stock: 50×)  1× (stock: 50×) 
 Mouse Recombinant EGF (Invitrogen, Cat #PMG8041)  50 ng/mL  50 ng/mL 
 Mouse Recombinant Noggin (Peprotech, Cat #250-38)  100 ng/mL  100 ng/mL 
 Human Recombinant RSPO1 (R&D Systems, Cat 
#4645-RS-025) b 
 500 ng/mL  500 ng/mL 
 Wnt3a (Cell Guidance Systems, Cat # GFM77)  –  100 ng/mL 
 Gastrin (Sigma-Aldrich, Cat # SCP0152)  –  15 nM 
 Nicotinamide (Sigma-Aldrich, Cat # N0636)  –  10 mM 
 P38 Mapk inhibitor SB202190 (Sigma-Aldrich, Cat # 
S7067) 
 –  10 μM 
 TGFb tyoe Itrecepror inhibitor A83-01 (Tocris, Cat # 
2939) 
 –  600 nM 
 N -Acetylcysteine (Sigma-Aldrich, Cat # A9165-5G)  –  12.5 mM 
 Primocin (Invitrogen, Cat # ant-pm-1)  –  100 μg/mL 
 For the protocol used for the isolation and cultivation of human intestinal organoids we refer to 
Sato et al. ( 2011a ,  b ) 
 a The mouse organoid culture protocol was adapted from Sato et al. ( 2009 ) 
 b Instead of using the commercially available RSPO1, one can culture transfected HEK293 cells, 
which carry a plasmid encoding mRSPO1-Fc (construct developed by Dr. Calvin Kuo at Stanford 
University, La Jolla, CA). For the protocol for HEK293 RSPO1 production, we refer to Carmon 
et al. ( 2011 ) and the ATCC website:  http://www.lgcstandards-atcc.org/en.aspx 
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and cultured from human induced pluripotent stem cells (iPPS), as described by 
McCracken et al. ( 2011 ), most studies culture organoids from mature stem cells 
from the intestinal crypt regions. The reason for this is that this method described is 
relatively elaborative and it takes much longer to mature the intestinal organoids in 
culture compared to the other method based on the organoid culture from adult 
intestinal cells. For a detailed protocol of iPPS-based culture of the intestinal tissue 
we refer to McCracken et al. ( 2011 ). As mentioned previously, lineage studies con-
fi rmed the stem cell hierarchy in intestinal organoids, either by fast cycling Lgr5+- 
or slowly cycling Bmi1+-stem cell activity (Sangiorgi and Capecchi  2008 ; Sato 
et al.  2009 ). Stem cell-based organoid cultures are an attractive model due to the 
presence of the self-renewing capacity; they can be passaged every 5–7 days. In 
addition, the structure and hierarchy of the mature organoids (after 5–7 days of 
culturing), highly resembles the in vivo intestinal epithelium (Fig.  22.1 ). Similar to 
the intestinal epithelium, stem cells and highly proliferative transit amplifying cells 
reside in the crypt-like domain of the organoids (Fig.  22.1 ). Differentiated cell types 
reside in the villus-region of the organoids and include enterocytes, goblet cells, 
Paneth cells, and enteroendocrine cells. These cells can be identifi ed using immu-
nohistochemistry with intestinal epithelial cell-specifi c markers. 
22.4  General Advantages and Limitations of Intestinal 
Organoid Systems 
 Despite the described signifi cant advances in culturing organoids, this system has 
some limitations. A major advantage of intestinal models in which an apical to 
basolateral polarity is preserved is the possibility to characterize epithelial transport 
mechanisms and barrier integrity upon exposure to microorganisms and microbial 
components. Indeed intestinal organoids consist of polarised, columnar epithelia. 
However, the inwards orientation of the epithelia (i.e. villi protrude into the lumen 
 Fig. 22.3  Phase contrast images of a developing mouse intestinal crypt into a organoid in 
culture. ( a ) immature organoid in culture 0.5–1 day after crypt isolation; ( b ) mature organoid 
in culture 3–5 days after crypt isolation; ( c ) mature organoid in culture 5–14 days after crypt 
isolation, ready to be passaged (note the accumulated debris of dead cells in the lumen of the 
organoid). This morphology is representative for other species as well [image adapted from 
Lukovac et al. ( 2014 )] 
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of the organoids) makes the apical side relatively inaccessible for direct experimen-
tal stimulation (Fig.  22.1 ). 
 Also, the organoids lack several essential components of the living digestive 
tract, such as the enteric nervous system, the vascular system, lymphatic systems 
and functional adaptive and innate immune systems. Additionally, the 3D architec-
ture is not as regular as seen in vivo, and the crypt-villus structures are variable in 
size and shape from one organoid to another. 
 Regardless of these drawbacks, this model offers great experimental utility for 
understanding and modeling human intestinal development, physiology, and host–
microbe interactions. Indeed, this model has several other advantages, such as a 
long-term culturing, broad range host species and GI tract compartments (stomach, 
ileum, colon) and gene manipulation possibilities (Koo et al.  2011 ). Moreover, this 
system provides a viable starting point for the development of screening platforms 
for pharmaceutical and food compounds. 
 Further expansion of this system will lead to broader application range and 
expansion of the read out possibilities. One example is transition of the existing 
system towards a structure with the apical/luminal compartment exposed on the 
outer site of the organoids, which will make the apical site of the organoids experi-
mentally more accessible. Furthermore, this system might be a promising tool in 
studies on epithelial interactions with food bioactive in individual subjects, as it has 
been demonstrated that organoids can be cultured from human intestinal biopsy 
samples (Sato et al.  2011b ). 
 Open Access  This chapter is distributed under the terms of the Creative Commons Attribution 
Noncommercial License, which permits any noncommercial use, distribution, and reproduction in 
any medium, provided the original author(s) and source are credited. 
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